ONTOZRY® (Cenobamate) Receives European Commission Approval for the Treatment of Drug-Resistant Focal-Onset Seizures in Adults

PANGYO, GYEONGGI PROVINCE, Korea, March 30, 2021 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a global innovative pharmaceutical company, announced today that cenobamate received marketing authorization from the European Commission (EC) under the brand name ONTOZRY® for the...

from PR Newswire: https://ift.tt/3cDQsHI